Literature DB >> 31100523

Podoplanin Expression and IDH-Wildtype Status Predict Venous Thromboembolism in Patients with High-Grade Gliomas in the Early Postoperative Period.

Jun Watanabe1, Manabu Natsumeda2, Masayasu Okada2, Yu Kanemaru2, Yoshihiro Tsukamoto2, Makoto Oishi2, Akiyoshi Kakita3, Yukihiko Fujii2.   

Abstract

OBJECTIVE: Venous thromboembolism (VTE) often is encountered in patients with high-grade gliomas. The underlying mechanisms are unclear, as is the optimal prophylactic protocol. The purpose of the present study was to identify risk factors of VTE and examine the validity of early VTE detection in high-grade gliomas.
METHODS: We reviewed the medical records of 165 patients with newly diagnosed high-grade glioma treated at Niigata University Hospital during the years 2009 to 2016. If the serum D-dimer levels increased to 5.0 μg/mL or more, computed tomography was performed to detect VTE. Furthermore, immunohistochemistry with antibodies against podoplanin was performed on available 101 tumor tissues.
RESULTS: Of the 165 patients, 44 (26.7%) developed VTE. Of the 44 patients, 34 (79.5%) developed VTE within 7 days after surgery. No fatal VTE occurred and major complications secondary to anticoagulation occurred in only 2 (1.2%) patients. On multivariate analysis, lower Karnofsky Performance Scale status, podoplanin expression, and isocitrate dehydrogenase-wildtype status were independently associated with the risk of VTE (P < 0.05).
CONCLUSIONS: We found that most VTEs occurred early in the postoperative period and commonly in patients with lower Karnofsky Performance Scale status and isocitrate dehydrogenase-wildtype gliomas, which expressed podoplanin.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  D-dimer; Deep venous thrombosis; Isocitrate dehydrogenase; Malignant glioma; Podoplanin; Venous thromboembolism

Year:  2019        PMID: 31100523     DOI: 10.1016/j.wneu.2019.05.049

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  6 in total

Review 1.  Mechanisms and biomarkers of cancer-associated thrombosis.

Authors:  Ann S Kim; Alok A Khorana; Keith R McCrae
Journal:  Transl Res       Date:  2020-07-06       Impact factor: 7.012

2.  Extracellular Vesicle Mediated Vascular Pathology in Glioblastoma.

Authors:  Cristiana Spinelli; Nadim Tawil; Lata Adnani; Janusz Rak; Dongsic Choi
Journal:  Subcell Biochem       Date:  2021

Review 3.  Venous Thrombotic Events and Anticoagulation in Brain Tumor Patients.

Authors:  Maria Diaz; Jasmin Jo
Journal:  Curr Oncol Rep       Date:  2022-02-18       Impact factor: 5.075

4.  Association between IDH mutational status and tumor-associated epilepsy or venous thromboembolism in patients with grade II and III astrocytoma.

Authors:  Yoshinari Osada; Ryuta Saito; Satoshi Miyata; Takuhiro Shoji; Ichiyo Shibahara; Masayuki Kanamori; Yukihiko Sonoda; Toshihiro Kumabe; Mika Watanabe; Teiji Tominaga
Journal:  Brain Tumor Pathol       Date:  2021-07-16       Impact factor: 3.298

5.  Biomarker signatures in cancer patients with and without venous thromboembolism events: a substudy of CASSINI.

Authors:  Alok A Khorana; John Barnard; Ted Wun; Ujjwala Vijapurkar; C V Damaraju; Kenneth Todd Moore; Peter Wildgoose; Keith R McCrae
Journal:  Blood Adv       Date:  2022-02-22

6.  Risk of Venous Thromboembolism in Grade II-IV Gliomas as a Function of Molecular Subtype.

Authors:  Maria Diaz; Jasmin Jo; Mark Smolkin; Sarah Jane Ratcliffe; David Schiff
Journal:  Neurology       Date:  2020-12-22       Impact factor: 9.910

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.